From the GALAHAD study, which has investigated treatments of castration-resistant prostatic carcinoma with Niraparib, it emerged that 65% of patients’ diagnoses with a BRCA1/2-mutated prostate carcinoma and 31% of patients with alternative DNA-repair gene mutated prostate cancer achieved a composite response [28]. Here, BRCA1 is linked to prostate carcinoma.